Kiniksa Pharmaceuticals International KNSA
NASDAQ KNSA
$75.73 -0.37 (-0.49%)
At close: Sep 29, 2026 · 4:00 PM EDT

Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026)

Updated

Kiniksa Pharmaceuticals International's Research & Development was $40.9 million in Q2 2026, up 118.1% from $18.75 million a year earlier and up 48.9% from the prior quarter.

Analysis

Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026) Analysis & Trends

On a trailing twelve-month basis, Kiniksa Pharmaceuticals International's Research & Development was $127.15 million through Jun 30, 2026, up 28.0% year-over-year; for FY2025, it was $96.85 million, down 13.2% from FY2024.

  • Research & Development shows a five-year compound annual growth rate of -2.9% (FY2020 to FY2025).
  • In earlier years, Research & Development was $111.62 million in FY2024 (+46.7%), $76.1 million in FY2023 (+16.2%), $65.49 million in FY2022 (-34.0%) and $99.3 million in FY2021 (-11.4%).
  • The Q2 2026 figure marks the highest quarterly Research & Development since Q1 2019.
  • Compared with a year earlier, Research & Development was higher in four of the last eight quarters, with growth averaging 28.8%.
  • The best year-over-year quarter for Research & Development over five years was Q2 2026 (growth of 118.1%); the worst was Q4 2022 (a decline of 47.5%).
  • Per Business Quant data, KNSA's Research & Development in the three quarters before Q2 2026 was $27.48 million (Q1 2026), $34.61 million (Q4 2025) and $24.17 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Kiniksa Pharmaceuticals International 11.87 Bn 10.61 Bn 220.03 Mn 40.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 40.90 Mn
Mar 31, 2026 27.48 Mn
Dec 31, 2025 34.61 Mn
Sep 30, 2025 24.17 Mn
Jun 30, 2025 18.75 Mn
Mar 31, 2025 19.33 Mn
Dec 31, 2024 35.22 Mn
Sep 30, 2024 26.06 Mn
Jun 30, 2024 24.02 Mn
Mar 31, 2024 26.33 Mn
Dec 31, 2023 20.05 Mn
Sep 30, 2023 17.11 Mn
Jun 30, 2023 23.77 Mn
Mar 31, 2023 15.17 Mn
Dec 31, 2022 14.39 Mn
Sep 30, 2022 16.49 Mn
Jun 30, 2022 13.80 Mn
Mar 31, 2022 20.82 Mn
Dec 31, 2021 27.43 Mn
Sep 30, 2021 19.24 Mn
API Access

Kiniksa Pharmaceuticals International Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=KNSA&period=max&api_key=YOUR_API_KEY